PHAXIAM Therapeutics: Company Research Report
Company Overview
Name: PHAXIAM Therapeutics
Mission: To develop innovative phage-based therapies to combat severe antibiotic-resistant bacterial infections and ultimately become a world leader in phage therapy.
Founded:
- PHAXIAM was established in June 2023 through the merger of two French biotechnology companies: ERYTECH and PHERECYDES.
- ERYTECH was founded in 2004 in Lyon, focusing originally on cancer therapies.
- PHERECYDES was established in 2007, specializing in precision phage therapy.
Key People:
- Thibaut du Fayet, CEO - With over 20 years of experience in pharmaceuticals and life sciences, previously at Rhône Poulenc and BioMerieux.
- Frédéric Mathat, CFO - Formerly at Nexity and Erytech.
- Pascal Birman, MD, CMO - Experienced in endocrinology and pharmaceutical development.
- Jérôme Bailly, Pharm.D., Deputy CEO, Quality Director, - with expertise in biotech production.
- Cindy Fevre, Chief Scientific Officer - Microbiologist with expertise in bacteriology.
Headquarters: 60, avenue Rockefeller, Bâtiment Bioserra, 69008 Lyon, France
Number of Employees: No information is available.
Revenue: No information is available.
Known For: Developing phage-based antibacterial treatments targeting antibiotic-resistant bacteria.
Products
Phage Therapy
Description:
- Antibacterial treatments based on bacteriophage viruses (or phages) targeting bacterial infections in humans, especially those resistant to antibiotics.
- Innovatively utilizes precise phage therapy to specifically target bacteria causing infections, minimizing damage to the human microbiota.
Key Features:
- Ultra-targeted eradication of specific bacteria.
- Quickly adaptable to bacterial mutations.
- Excellent efficacy and tolerance due to high specificity.
Target Pathogens:
- Staphylococcus aureus
- Escherichia coli
- Pseudomonas aeruginosa
Recent Developments
Collaboration with Technophage:
- Announced in January 2025, focusing on individualized phage therapies (IPT) by combining their phage portfolios to cover critical pathogens.
- Portfolio expansion to 25 phages by end 2025, targeting 7 pathogens, aimed at accelerating access to IPT in Europe.
FDA Study Clearance:
- In November 2024, PHAXIAM received FDA clearance to initiate the Phase II GLORIA study in the U.S. for infections due to Staphylococcus aureus in prosthetic joints (PJI), a vital step for global clinical development.
Clinical Data Results:
- Promising results reported in January 2025 from 88 European patients treated compassionately with phages, showing effective infection control.
- Ongoing global Phase II GLORIA trial for the efficacy of phage therapy in PJIs.
Financial Developments:
- Financial calendar for 2025 includes updates on annual results and aims to generate significant revenue through IPT by 2027.
Strategic Developments:
- Focus on phage-medicines (PTMP) development parallel to IPT model.
- Active pursuit of both dilutive and non-dilutive funding to sustain operations beyond March 2025.
This comprehensive report provides insights into PHAXIAM Therapeutics and its current strategic initiatives, highlighting the importance of their innovative phage therapy solutions in combating antibiotic-resistant infections.
